Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EROICA: Switching from low/moderate-intensity statin to ezetimibe + low-dose rosuvastatin in type 2 diabetes mellitus with dyslipidemia
KCT0008224Phase 4Terminated
- Sponsor
- Hanmi Pharmaceutical
- Start
- Apr 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ezetimibe, rosuvastatin in type 2 diabetes mellitus (T2DM), dyslipidemia, sponsored by Hanmi Pharmaceutical. Started Apr 2023; status: terminated.
02
Drugs
ezetimiberosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on KCT0008224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008224.